Mazdutide is a GLP-1/glucagon dual agonist, approved in China for weight management and nowhere else. Its human evidence is one Phase 3 program, run in China, reporting about 14% mean weight loss at 48 weeks. That's the lowest number any dual agonist has published.
Mazdutide is a GLP-1/glucagon dual agonist built on an oxyntomodulin backbone. Innovent Biologics developed it under license from Eli Lilly. China has approved it for weight management. Its Phase 3 GLORY-1 trial showed about 14% mean body-weight loss at 48 weeks. That is the lowest figure among the dual agonists. It is roughly semaglutide territory.
What is mazdutide built from?
Mazdutide is an engineered copy of oxyntomodulin, a gut hormone your body already makes. Oxyntomodulin switches on both the GLP-1 receptor and the glucagon receptor. So the dual-agonist behavior isn't bolted on. It was there in the parent molecule.
What Innovent's chemists added was staying power. Native oxyntomodulin clears in minutes, so the analog carries a half-life extension that makes weekly dosing workable.
That's a different design philosophy from the rest of the class. Tirzepatide and retatrutide start from a GIP backbone and have receptor activity engineered in. Mazdutide starts from a molecule that already had the receptor profile, and engineers the pharmacokinetics instead.
Whether the biomimicry buys anything in the clinic is still open. We read the GLORY-1 result as no argument either way, and we'd rather say that than dress a design story up as a finding.
How much weight did mazdutide produce in GLORY-1?
About 14% mean body-weight reduction at the top dose, over 48 weeks, in a Chinese Phase 3 trial. That places mazdutide near semaglutide and below tirzepatide, CagriSema and survodutide.
It's a mildly surprising result. Everywhere else in this class, adding a second receptor has bought magnitude. Here it didn't.
- Trial: GLORY-1, Phase 3, run in China, published in the New England Journal of Medicine in 2025.
- Duration: 48 weeks.
- Headline result: roughly 14% mean body-weight reduction at the top dose.
- Class position: semaglutide territory, below every other dual agonist with published Phase 3 data.
- Western data: none. No FDA or EMA trial program exists.
Where this falls short. GLORY-1 ran in a Chinese population. Baseline BMI distributions differ a lot between Chinese and Western obesity cohorts.
Percentage weight reduction doesn't port cleanly across populations that start from different weights. That's one reason cross-trial comparison in this class is harder than a bar chart makes it look. If you're ranking these compounds against each other, treat the 14% as a Chinese-cohort number, not a universal one.
Is mazdutide approved anywhere?
Yes, in China, for weight management. Mazdutide has no FDA approval and no EMA approval, and the development program has pointed at the Chinese market throughout.
For the most commercially contested drug class in the world, that's a deliberately narrow footprint. It also means the safety record you can read is a Chinese one, and there's no Western regulatory review to check it against.
Metabolic research compounds
Mazdutide isn't stocked. The GLP-1 class compounds that are — single, dual and triple agonists — are in the catalog, each with a batch-matched certificate of analysis.
For where mazdutide sits against the rest of the class, see our 2026 comparison. For the other GLP-1/glucagon dual agonist still in development, see survodutide.
Frequently asked questions
What is mazdutide?
Mazdutide is a GLP-1/glucagon dual agonist based on an oxyntomodulin analog. Innovent Biologics developed it under license from Eli Lilly, mainly for the Chinese market. It completed Phase 3 in China as the GLORY-1 trial.
How much weight does mazdutide produce?
Roughly 14% mean body-weight reduction at the top dose in GLORY-1, over 48 weeks. That's about semaglutide territory, and below the other dual agonists in the class.
Is mazdutide approved?
Mazdutide is approved in China for weight management. It isn't approved by the FDA or the EMA, so you won't find it through any US or European prescription channel.
How is mazdutide different from survodutide?
Both are GLP-1/glucagon dual agonists. Mazdutide is built on oxyntomodulin, the natural gut hormone that hits both receptors, so it's the more biomimetic of the two. It also produced the smaller weight effect in trials.
Metabolic research compounds
Third-party tested research compounds, each shipped with a batch-matched certificate of analysis showing HPLC purity and mass-spec identity — the documentation this site argues you should hold any supplier to.
What to know now
- Mazdutide is a GLP-1/glucagon dual agonist built on an oxyntomodulin backbone, the gut hormone that already hits both receptors.
- Innovent Biologics developed it under license from Eli Lilly, and China has approved it for weight management.
- The Phase 3 GLORY-1 trial reported about 14% mean body-weight loss at 48 weeks, the lowest figure among the dual agonists.
- It has no FDA or EMA approval, and the program has stayed oriented to China, so no Western trial exists.
- GLORY-1 ran in a Chinese cohort, and percentage weight loss does not port cleanly across populations with different baseline BMI.
What we’re watching
The thing we're waiting on is a Western trial. Until one runs, every figure on this page comes from a single Chinese Phase 3 program, and nobody outside that program has reproduced it.
We're also watching whether the oxyntomodulin design shows up anywhere in the safety data. A biomimetic backbone is a reasonable hypothesis about tolerability. It isn't a result yet.
References
- Ji, L., Jiang, H., Bi, Y., et al. (2025). Once-weekly mazdutide in Chinese adults with obesity or overweight. New England Journal of Medicine, 392(22), 2215–2225. https://doi.org/10.1056/NEJMoa2411528
- Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2024). What is the pipeline for future medications for obesity? International Journal of Obesity, 49(3), 433–451. https://doi.org/10.1038/s41366-024-01473-y
- Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP-1). New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183